Although the prognostic impact of the CLL-IPI on OS is lower in the era of targeted agents, our results demonstrate that elevated B2M plasma levels alone serve as an independent prognostic parameter in both treatment eras. This evidence concerns the gene B2M and B-cell chronic lymphocytic leukemia.